Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.3% - Here's What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares fell 1.3% during trading on Thursday . The company traded as low as $7.97 and last traded at $8.24. 8,988,098 shares traded hands during trading, a decline of 65% from the average session volume of 25,388,480 shares. The stock had previously closed at $8.34.

Analyst Ratings Changes

A number of brokerages recently commented on RXRX. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of "Hold" and an average target price of $8.25.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $2.93 billion, a P/E ratio of -4.91 and a beta of 0.86. The company has a 50 day moving average price of $7.72 and a 200-day moving average price of $7.09. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the previous year, the company posted ($0.42) EPS. The company's revenue for the quarter was down 57.8% compared to the same quarter last year. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at $26,000. Private Trust Co. NA acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at $27,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.